Weak Trigger
now
Phase 2 interim data for autoimmune candidate 'NKTR-255' hits primary efficacy endpoint by exceeding target T-cell activation ratios by 35%.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |